KRRO — Korro Bio Cashflow Statement
0.000.00%
- $395.83m
- $299.46m
- $2.27m
Annual cashflow statement for Korro Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -22 | -58 | -81.2 | -83.6 |
| Depreciation | ||||
| Non-Cash Items | -12.6 | 2.51 | 5.98 | 6.35 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.904 | -0.633 | 4.28 | 13.6 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -32.1 | -53.6 | -67.3 | -60.1 |
| Capital Expenditures | -3.75 | -5.14 | -7.84 | -17.9 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -35.7 | 16.2 | 19 | -105 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Change in Net Investments | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -39.5 | 11.1 | 11.2 | -123 |
| Financing Cash Flow Items | -0.03 | -0.044 | 24.4 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 116 | 0.018 | 188 | 69.4 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 44.4 | -42.6 | 132 | -114 |